Genetic variation in key cell pumping mechanism reduces effects of clopidogrel treatment

A study published Online First and in an upcoming Lancet shows that patients with a genetic variation affecting a key protein pump in drug transport do not respond as well to the anticlotting drug clopidogrel -as such, patients with this variation at are at increased risk of cardiovascular events with standard clopidogrel treatment. However, no association exists between this genetic variation and another anticlotting drug, prasugrel.

Read the whole article on Physorg

More from Physorg